Tsuyoshi Majima Selected Research

silodosin

4/2021	Effects of tadalafil versus silodosin on voiding function in male patients with non-neurogenic detrusor underactivity: A comparative study using propensity score matching.
1/2019	Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
9/2018	Two-year follow up of silodosin on lower urinary tract functions and symptoms in patients with benign prostatic hyperplasia based on prostate size: a prospective investigation using urodynamics.
10/2017	Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
1/2017	Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
1/2017	Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms.
1/2017	Intraprostatic Reflux of Urine Induces Inflammation in a Rat.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tsuyoshi Majima Research Topics

Disease

11	Lower Urinary Tract Symptoms 04/2023 - 01/2017
11	Urinary Bladder Neck Obstruction (Bladder Neck Obstruction) 01/2023 - 01/2017
7	Overactive Urinary Bladder (Overactive Bladder) 01/2020 - 01/2017
6	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 05/2019 - 06/2014
5	Urinary Incontinence 04/2021 - 01/2019
5	Spinal Cord Injuries (Spinal Cord Injury) 01/2018 - 01/2017
5	Cystitis 02/2017 - 04/2014
4	Neoplasms (Cancer) 01/2020 - 05/2014
4	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 01/2018
4	Inflammation (Inflammations) 01/2017 - 04/2014
3	Underactive Urinary Bladder 04/2023 - 08/2020
3	Stress Urinary Incontinence 01/2019 - 07/2012
3	Pain (Aches) 01/2018 - 11/2015
2	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2020 - 01/2019
2	Hypersensitivity (Allergy) 01/2019 - 01/2017
2	Interstitial Cystitis (Interstitial Cystitis, Chronic) 01/2017 - 01/2017
1	COVID-19 01/2023
1	Carcinoma (Carcinomatosis) 01/2023
1	Hypertrophy 08/2020
1	Brain Neoplasms (Brain Tumor) 01/2019
1	Cerebral Hemorrhage 01/2019
1	Rhabdomyosarcoma 01/2019
1	Sarcopenia 01/2019
1	Margins of Excision 01/2019
1	Inguinal Hernia (Direct Inguinal Hernia) 06/2018
1	Colitis 01/2018
1	Ischemia 08/2017
1	Fibrosis (Cirrhosis) 08/2017
1	Hypoxia (Hypoxemia) 01/2017
1	Autonomic Dysreflexia 01/2017
1	Lymphatic Metastasis 10/2012
1	Necrosis 10/2012

Drug/Important Bio-Agent (IBA)

7	silodosin FDA Link 04/2021 - 01/2017
5	Tadalafil (Cialis)FDA Link 04/2021 - 08/2017
4	Therapeutic UsesIBA 12/2020 - 11/2015
4	Prostate-Specific Antigen (Semenogelase)IBA 01/2020 - 01/2017
4	naftopidilIBA 01/2019 - 01/2017
4	Messenger RNA (mRNA)IBA 01/2018 - 03/2015
4	Proteins (Proteins, Gene)FDA Link 01/2017 - 06/2014
3	2- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA 01/2023 - 01/2019
3	Nerve Growth Factor (NGF)IBA 01/2018 - 01/2017
3	Liposomes (Liposome)IBA 01/2017 - 01/2017
2	mirabegronIBA 08/2020 - 01/2019
2	salicylhydroxamic acid (SHAM)IBA 08/2020 - 01/2017
2	AndrogensIBA 01/2020 - 03/2015
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019 - 04/2014
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2018 - 01/2017
2	Capsaicin (Zostrix)FDA Link 01/2018 - 01/2017
2	resiniferatoxinIBA 01/2018 - 01/2017
2	Dutasteride (Avodart)FDA Link 10/2017 - 09/2017
2	Adrenergic Receptors (Adrenergic Receptor)IBA 08/2017 - 01/2017
2	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 02/2017 - 01/2017
2	Eosine Yellowish-(YS) (Eosin)IBA 03/2015 - 04/2014
2	Hematoxylin (Haematoxylon)IBA 03/2015 - 04/2014
2	rebamipideIBA 12/2014 - 04/2014
1	AdiponectinIBA 04/2023
1	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2021
1	Testosterone (Sustanon)FDA Link 12/2020
1	indolepropanol phosphate (IPP)IBA 01/2020
1	Serum AlbuminIBA 01/2019
1	C-Reactive ProteinIBA 01/2019
1	fesoterodine FDA Link 01/2019
1	Vincristine (Oncovin)FDA LinkGeneric 01/2019
1	Dactinomycin (Actinomycin)FDA LinkGeneric 01/2019
1	AlbuminsIBA 01/2019
1	Phosphoprotein Phosphatases (Phosphatases, Protein)IBA 01/2019
1	Sulfonic AcidsIBA 01/2018
1	Minocycline (Cyclops)FDA LinkGeneric 01/2018
1	ProstaglandinsIBA 01/2018
1	CollagenIBA 08/2017
1	ElastinIBA 08/2017
1	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 08/2017
1	Phosphodiesterase 5 InhibitorsIBA 08/2017
1	8-Hydroxy-2'-DeoxyguanosineIBA 05/2017
1	diamidino compound 253-50IBA 01/2017
1	SphingomyelinsIBA 01/2017
1	Botulinum Toxins (Botulinum Toxin)IBA 01/2017
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2017
1	Antisense OligonucleotidesIBA 01/2017
1	TRPV1 receptorIBA 11/2015
1	EnzymesIBA 03/2015
1	ImmunosorbentsIBA 03/2015
1	Transforming Growth Factor beta (TGF-beta)IBA 03/2015
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 03/2015

Therapy/Procedure

8	Prostatectomy (Retropubic Prostatectomy) 04/2021 - 01/2018
7	Therapeutics 01/2023 - 01/2017
2	Drug Therapy (Chemotherapy) 01/2019 - 04/2014
2	Aftercare (After-Treatment) 01/2019 - 01/2018
2	Intravesical Administration 02/2017 - 01/2017
2	Cell- and Tissue-Based Therapy (Cell Therapy) 03/2014 - 07/2012
1	Nephroureterectomy 01/2023
1	Urinary Catheters 04/2021
1	Solid-State Lasers 01/2019
1	Lasers (Laser) 01/2017
1	Nephrectomy 05/2014
1	Warm Ischemia 05/2014
1	Adjuvant Chemotherapy 10/2012